Lung cancer drug shows promise after standard treatment
NCT ID NCT07050472
First seen Feb 12, 2026 · Last updated May 18, 2026 · Updated 11 times
Summary
This study looked at 45 people with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. Researchers measured how long patients lived without their cancer getting worse. The goal was to see if adding durvalumab helps control the disease longer in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital and Institute
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.